ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Beryl Drugs Q4 FY26 Results: Net Profit ₹0.6 Cr, Up 200.0% YoY

Beryl Drugs Ltd reported revenue from operations of ₹5.5 Cr (+5.8% YoY) and net profit of ₹0.6 Cr (+200.0% YoY) for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations5.53.95.2
Total income5.53.95.2
Profit before exceptional items & tax0.9-0.60.1
Profit before tax0.9-0.60.1
Net profit0.6-0.20.2
Operating margin16.4%-15.4%1.9%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year+200.00%
Revenue, year on year+5.80%
Source

BSE results filing, NSE: BERLDRG. Figures extracted from the filing.

Read the filing ↗

Beryl Drugs Ltd: key numbers

Share price
₹26.00
Market cap
₹13.19 Cr
Revenue (annual)
₹18.82 Cr
Net profit (annual)
₹0.42 Cr
P/E (TTM)
21.1×Sector 43.8×
Promoter holding
27.97%+0.15% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Beryl Drugs Ltd

All →